OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY

Go Back to All Clinical Trials

OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY

Brief description of study

This study is for patients with early-stage triple-negative breast cancer who received a treatment called pembrolizumab (a medicine used to treat melanoma). Some patients will continue to get pembrolizumab, while others will simply be observed without more treatment. The main question is whether observation is as good as getting more pembrolizumab to prevent the cancer from coming back. The study looks at other things like side effects, quality of life, survival.

Clinical Study Identifier: s23-00607

Principal Investigator: Sylvia Adams.

Other Investigators: Yelena Novik, Maryann J Kwa, Douglas K Marks, Nina D'Abreo, Marleen I Meyers, Amanda Marie Talmadge, Danielle Seidman, Caitlin Elizabeth Ryan, Anastasiya Apanasyuk, Ruth Oratz, Natalie Jill Klar, Alexander A Hindenburg.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies